Clinical trials
Colitis, Ulcerative trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 32 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shandong University | 6 |
| The Second Hospital of Nanjing Medical University | 3 |
| Third Military Medical University | 3 |
| Affiliated Hospital to Academy of Military Medical Sciences | 2 |
| Xijing Hospital of Digestive Diseases | 2 |
| First Affiliated Hospital of Chengdu Medical College | 1 |
| First Affiliated Hospital of Kunming Medical University | 1 |
| Jinling Hospital, China | 1 |
| Liaocheng People's Hospital | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 32 |
| Crohn Disease | 5 |
| Inflammatory Bowel Diseases | 4 |
| Arthritis, Juvenile | 1 |
| Autoimmune Diseases | 1 |
| Dermatomyositis | 1 |
| Disease | 1 |
| Inflammation | 1 |
| Irritable Bowel Syndrome | 1 |
| Postoperative Complications | 1 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.